Draftly: $12,750 MRR from a one-prompt AI website builder, per payment data on TrustMRR
TrustMRR pulls this revenue from Dodo Payments. Draftly is a builder that creates an immersive website from a single prompt.
Subject: PIYUSH .S (Draftly)Monthly subscription ($25/mo Basic)
Case Overview & Background
Draftly was founded by PIYUSH .S and is a builder that creates an immersive website from a single prompt. TrustMRR shows $15,028 in the last 30 days, $12,750 MRR, $156,856 all-time revenue, 385 active subscriptions as of October 31, 2026.
How AI Is Used
Step-by-Step Process
The product focuses on one outcome: a builder that creates an immersive website from a single prompt.
Pricing on the listing: $25/mo for Draftly Basic.
Revenue is shared publicly through a Dodo Payments connection on TrustMRR.
Customer Acquisition & Distribution
Limitations, Risks & Failure Modes
What may not apply to you, and what could go wrong:
- Revenue is not profit; AI model, hosting and marketing costs are not shown
- Figures change daily; this is a snapshot from October 31, 2026
- Products built on third-party AI models depend on those providers' pricing and policies
Key Takeaways
- A narrow AI product with a clear outcome can be sold directly to consumers or businesses
- Payment-provider-verified figures are stronger than screenshots but are still not an audit
Sources
TrustMRR verified revenue page: Draftly
Note: Revenue pulled from Dodo Payments. Viewed October 31, 2026. Product description on the page is written by the founder.
Category page banner: Reach readers researching one specific AI business model.
One clearly labelled banner on a category page such as Micro-SaaS or AI Agencies, shown next to the documented cases your product is relevant to.
Sponsored placements are always labelled and never change how cases are researched, labelled, or ranked.
Commercial disclosure: We currently have no affiliate or sponsorship relationship with any tool or person on this page. If that changes, affiliate links and sponsored content will be clearly labelled, and evidence labels will never be changed for commercial reasons.
